These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18172943)

  • 21. Obsessive compulsive disorder.
    Soomro GM
    Clin Evid; 2005 Dec; (14):1270-83. PubMed ID: 16620454
    [No Abstract]   [Full Text] [Related]  

  • 22. Obsessive compulsive disorder.
    Soomro GM
    Clin Evid; 2004 Jun; (11):1319-34. PubMed ID: 15652061
    [No Abstract]   [Full Text] [Related]  

  • 23. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obsessive-compulsive disorder in Tourette syndrome.
    Goodman WK; Storch EA; Geffken GR; Murphy TK
    J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment.
    Tenneij NH; van Megen HJ; Denys DA; Westenberg HG
    J Clin Psychiatry; 2005 Sep; 66(9):1169-75. PubMed ID: 16187776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.
    Van Ameringen M; Simpson W; Patterson B; Dell'Osso B; Fineberg N; Hollander E; Hranov L; Hranov G; Lochner C; Karamustafalioglu O; Marazziti D; Menchon JM; Nicolini H; Pallanti S; Stein DJ; Zohar J
    J Psychopharmacol; 2014 Jun; 28(6):596-602. PubMed ID: 24429223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Novel treatment strategies for refractory patients with obsessive-compulsive disorder].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2013; 115(9):997-1003. PubMed ID: 24228478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap.
    Szechtman H; Harvey BH; Woody EZ; Hoffman KL
    Pharmacol Rev; 2020 Jan; 72(1):80-151. PubMed ID: 31826934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment strategies for chronic and refractory obsessive-compulsive disorder.
    Rasmussen SA; Eisen JL
    J Clin Psychiatry; 1997; 58 Suppl 13():9-13. PubMed ID: 9402914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological approaches to treatment-resistant obsessive compulsive disorder.
    Goodman WK; McDougle CJ; Barr LC; Aronson SC; Price LH
    J Clin Psychiatry; 1993 Jun; 54 Suppl():16-26. PubMed ID: 8331098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach.
    Uguz F
    Braz J Psychiatry; 2015; 37(4):334-42. PubMed ID: 26692431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obsessive-compulsive disorder: a critical review of therapeutic perspectives.
    Schruers K; Koning K; Luermans J; Haack MJ; Griez E
    Acta Psychiatr Scand; 2005 Apr; 111(4):261-71. PubMed ID: 15740462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.
    Oulis P; Mourikis I; Konstantakopoulos G
    Int Clin Psychopharmacol; 2011 Jul; 26(4):221-4. PubMed ID: 21460732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the treatment for refractory obsessive-compulsive disorder: from medicine to deep brain stimulation.
    Husted DS; Shapira NA
    CNS Spectr; 2004 Nov; 9(11):833-47. PubMed ID: 15520607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series.
    Dell'Osso B; Mundo E; Altamura AC
    CNS Spectr; 2006 Nov; 11(11):879-83; quiz 885. PubMed ID: 17075559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.